301230 泓博医药
已收盘 01-09 15:00:00
资讯
新帖
简况
异动快报：泓博医药（301230）1月9日14点38分触及涨停板
证券之星 · 01-09 14:40
异动快报：泓博医药（301230）1月9日14点38分触及涨停板
1月8日泓博医药涨6.61%，长城消费增值混合A基金重仓该股
证券之星 · 01-08 15:41
1月8日泓博医药涨6.61%，长城消费增值混合A基金重仓该股
泓博医药（301230）披露2025年前三季度权益分派实施公告，1月7日股价上涨1.1%
证券之星 · 01-07 22:30
泓博医药（301230）披露2025年前三季度权益分派实施公告，1月7日股价上涨1.1%
1月5日泓博医药涨7.30%，长城消费增值混合A基金重仓该股
证券之星 · 01-05
1月5日泓博医药涨7.30%，长城消费增值混合A基金重仓该股
泓博医药：本次股份转让系部分外部投资者的自身资金需求
证券之星 · 01-05
泓博医药：本次股份转让系部分外部投资者的自身资金需求
泓博医药：本次股份转让无预设折价或溢价安排
证券之星 · 01-05
泓博医药：本次股份转让无预设折价或溢价安排
每周股票复盘：泓博医药（301230）股东减持5%股份
证券之星 · 01-03
每周股票复盘：泓博医药（301230）股东减持5%股份
泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份
证券之星 · 2025-12-24
泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份
股市必读：泓博医药（301230）12月22日董秘有最新回复
证券之星 · 2025-12-23
股市必读：泓博医药（301230）12月22日董秘有最新回复
泓博医药：未与阿里等开展C端健康医疗合作
证券之星 · 2025-12-22
泓博医药：未与阿里等开展C端健康医疗合作
泓博医药：公司需严格履行相关保密义务
证券之星 · 2025-12-22
泓博医药：公司需严格履行相关保密义务
泓博医药：截至2025年12月10日股东户数为14,645户
证券之星 · 2025-12-15
泓博医药：截至2025年12月10日股东户数为14,645户
泓博医药：公司经营稳定业务持续向好
证券之星 · 2025-12-09
泓博医药：公司经营稳定业务持续向好
泓博医药：帕拉米韦适用于流感病毒引起的感冒
证券之星 · 2025-12-09
泓博医药：帕拉米韦适用于流感病毒引起的感冒
泓博医药（301230）披露2025年半年度权益分派实施公告，11月7日股价下跌2.06%
证券之星 · 2025-11-07
泓博医药（301230）披露2025年半年度权益分派实施公告，11月7日股价下跌2.06%
泓博医药（301230）4875.55万股限售股将于11月3日解禁，占总股本34.93%
证券之星 · 2025-11-03
泓博医药（301230）4875.55万股限售股将于11月3日解禁，占总股本34.93%
泓博医药（301230）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 2025-10-31
泓博医药（301230）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%
智通财经 · 2025-10-29
泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%
泓博医药调整股权激励计划授予价格并完成预留授予
中金财经 · 2025-10-28
泓博医药调整股权激励计划授予价格并完成预留授予
股市必读：泓博医药（301230）9月25日董秘有最新回复
证券之星 · 2025-09-26
股市必读：泓博医药（301230）9月25日董秘有最新回复
加载更多
公司概况
公司名称：
上海泓博智源医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-11-01
主营业务：
上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。
发行价格：
40.00
{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":41.24,"timestamp":1767942228000,"preClose":34.37,"halted":0,"volume":26523111,"delay":0,"changeRate":0.1999,"floatShares":126000000,"shares":140000000,"eps":0.2622,"marketStatus":"已收盘","change":6.87,"latestTime":"01-09 15:00:00","open":35.5,"high":41.24,"low":34.99,"amount":1018000000,"amplitude":0.1818,"askPrice":0,"askSize":0,"bidPrice":41.24,"bidSize":8317,"shortable":0,"etf":0,"ttmEps":0.2622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":34.37,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":37.81,"lowLimit":30.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":4.68,"roa":"--","peRate":157.284516,"roe":"3.3%","epsLYR":0.12,"committee":0,"marketValue":5757000000,"turnoverRate":0.2111,"status":0,"floatMarketCap":5180000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2602203342","title":"异动快报：泓博医药（301230）1月9日14点38分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602203342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602203342?lang=zh_cn&edition=full","pubTime":"2026-01-09 14:40","pubTimestamp":1767940832,"startTime":"0","endTime":"0","summary":"证券之星1月9日盘中消息，14点38分泓博医药触及涨停板。其所属行业医疗服务目前上涨。领涨股为迪安诊断。该股为多模态，AI医疗，人工智能概念热股，当日多模态概念上涨5.13%，AI医疗概念上涨3.71%，人工智能概念上涨2.83%。1月8日的资金流向数据方面，主力资金净流入2016.16万元，占总成交额4.38%，游资资金净流出487.54万元，占总成交额1.06%，散户资金净流出1528.62万元，占总成交额3.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900018638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2601356463","title":"1月8日泓博医药涨6.61%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356463","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356463?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:41","pubTimestamp":1767858082,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日泓博医药涨6.61%创60日新高，收盘报34.37元，换手率10.64%，成交量13.36万手，成交额4.6亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为5.16亿元，最新净值1.2388，较上一交易日下跌0.91%，近一年上涨33.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2601801593","title":"泓博医药（301230）披露2025年前三季度权益分派实施公告，1月7日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801593","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801593?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:30","pubTimestamp":1767796240,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，泓博医药报收于32.24元，较前一交易日上涨1.1%，最新总市值为45亿元。该股当日开盘31.88元，最高32.89元，最低31.85元，成交额达1.59亿元，换手率为3.91%。公司于近日发布公告，披露2025年前三季度权益分派实施方案。股权登记日为2026年1月12日，除权除息日为2026年1月13日。公司回购专用账户中的股份不参与本次权益分派。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2601006593","title":"1月5日泓博医药涨7.30%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006593","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006593?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:46","pubTimestamp":1767599219,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日泓博医药涨7.30%，收盘报32.05元，换手率5.59%，成交量7.02万手，成交额2.22亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为5.16亿元，最新净值1.1061，较上一交易日上涨0.6%，近一年上涨17.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2601006884","title":"泓博医药：本次股份转让系部分外部投资者的自身资金需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006884","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006884?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:39","pubTimestamp":1767598764,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药01月04日在投资者关系平台上答复投资者关心的问题。本次股份转让相关情况详见公司于2025年12月31日披露的相关公告。该转让系部分外部投资者的自身资金需求，与公司经营无关。公司实控人及管理层未参与本次转让，其持股保持稳定。本次转让的受让方为专业机构投资者，受让股份有6个月的锁定期，有助于减少对市场的直接冲击、引入长期投资者，与公司及全体股东的利益高度一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2601855006","title":"泓博医药：本次股份转让无预设折价或溢价安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2601855006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601855006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:39","pubTimestamp":1767598763,"startTime":"0","endTime":"0","summary":"投资者提问：控股股东询价转让5%股权，是计划折价交易还是溢价交易？本次股份转让由证券公司组织实施，严格遵循现行证券市场的监管要求，不存在公司或股东预设的折价或溢价安排。本次转让的受让方为具备较强风险承受能力的专业机构投资者，受让股份有6个月的锁定期，该机制旨在引入长期投资者，减少对二级市场的冲击，与公司及全体股东的利益高度一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2600060333","title":"每周股票复盘：泓博医药（301230）股东减持5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2600060333","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600060333?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:26","pubTimestamp":1767381970,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，泓博医药报收于29.87元，较上周的29.37元上涨1.7%。本周，泓博医药12月31日盘中最高价报30.1元。转让后，出让方及一致行动人合计持股比例由44.94%降至39.94%。泓博医药简式权益变动报告书指出，泓博智源（香港）因自身资金需求，于2025年12月30日通过询价转让减持公司股份6,979,330股，占总股本5.00%。权益变动后，信息披露义务人合计持有公司股份55,746,970股，占总股本39.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2593347915","title":"泓博医药最新公告：股东泓博智源（香港）医药技术有限公司拟询价转让697.93万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593347915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593347915?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:00","pubTimestamp":1766574023,"startTime":"0","endTime":"0","summary":"泓博医药(301230.SZ)公告称，公司持股5%以上的股东泓博智源（香港）医药技术有限公司计划通过询价转让方式，转让其持有的697.93万股公司股份，占公司总股本的5.00%，占剔除公司回购专用账户后的总股本的5.07%。转让原因为自身资金需求。本次询价转让不通过集中竞价交易或大宗交易方式进行，受让方通过询价转让受让的股份在受让后6个月内不得转让。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0216","09939","BK1574","159938","BK1161","301230"],"gpt_icon":0},{"id":"2593432174","title":"股市必读：泓博医药（301230）12月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593432174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593432174?lang=zh_cn&edition=full","pubTime":"2025-12-23 02:34","pubTimestamp":1766428451,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，泓博医药报收于30.41元，下跌0.98%，换手率1.86%，成交量2.34万手，成交额7141.64万元。依托支付宝体系的 10 亿级用户基础，“阿福”有望成为高频健康交互入口。股价走势受宏观环境、行业周期及市场情绪等多重因素影响，涨跌属于市场行为。未来如有相关计划，公司将及时履行信息披露义务。当日关注点来自交易信息汇总：12月22日主力资金净流出410.78万元，游资资金净流入502.11万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300001379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2593544100","title":"泓博医药：未与阿里等开展C端健康医疗合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593544100?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391313,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药12月22日在投资者关系平台上答复投资者关心的问题。依托支付宝体系的 10 亿级用户基础，“阿福”有望成为高频健康交互入口。基于此，我司目前未与阿里巴巴或其他互联网平台开展C端健康医疗类项目合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200015593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","ALBmain","159891","301230"],"gpt_icon":0},{"id":"2593107755","title":"泓博医药：公司需严格履行相关保密义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107755?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:09","pubTimestamp":1766390950,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司跟礼来、诺和、辉瑞等这些公司或者他们旗下公司是否有相关合作？泓博医药回复：尊敬的投资者您好！公司服务的客户类型覆盖全球范围内的创新药企、制药企业、生物技术公司以及科研机构等。但根据合同约定及行业通行的商业保密要求，具体客户名称及合作细节不便对外披露，公司需严格履行相关保密义务，敬请理解。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200015016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2591116386","title":"泓博医药：截至2025年12月10日股东户数为14,645户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591116386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591116386?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:42","pubTimestamp":1765788133,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日股东人数是多少？泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2025年12月10日，公司的股东户数为14,645户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500018647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2590360301","title":"泓博医药：公司经营稳定业务持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590360301?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:00","pubTimestamp":1765242059,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药12月08日在投资者关系平台上答复投资者关心的问题。股价走势受宏观环境、行业周期及市场情绪等多重因素影响，涨跌属于市场行为。公司目前经营稳定，业务发展持续向好，公司管理层对公司的未来发展充满信心，并将持续聚焦主营业务，不断提升公司经营质量和盈利能力，致力于为投资者创造长期、可持续的价值回报。未来如有相关计划，公司将及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900004758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2590360302","title":"泓博医药：帕拉米韦适用于流感病毒引起的感冒","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590360302?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:00","pubTimestamp":1765242058,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：近期看新闻，全国流感爆发，公司的产品是否涉及相关流感类；如果是，那么是否带起公司近期产品销量？麻烦尽可能详细分享一下泓博医药回复：尊敬的投资者您好！帕拉米韦是公司的商业化品种之一，适用于流感病毒引起的普通流行性感冒、甲型流行性感冒或乙型流行性感冒。关于产品的经营情况敬请关注公司的定期报告，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900004752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2581881523","title":"泓博医药（301230）披露2025年半年度权益分派实施公告，11月7日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881523","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581881523?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:40","pubTimestamp":1762526435,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，泓博医药报收于32.31元，较前一交易日下跌2.06%，最新总市值为45.1亿元。该股当日开盘32.76元，最高32.8元，最低32.24元，成交额达7035.15万元，换手率为1.73%。公司近日发布公告，披露2025年半年度权益分派实施方案。本次权益分派股权登记日为2025年11月13日，除权除息日为2025年11月14日。现金红利将由中国结算深圳分公司代派，部分股东由公司自行派发。本次权益分派实施后，除权除息参考价将相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2580237230","title":"泓博医药（301230）4875.55万股限售股将于11月3日解禁，占总股本34.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237230","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580237230?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:02","pubTimestamp":1762128159,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，泓博医药于11月3日将有4875.55万股限售股份解禁，为公司首发原股东限售股份，占公司总股本34.93%。本次解禁后，公司还有1397.08万股限售股份，占总股本10.01%。泓博医药主营业务：药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2579104507","title":"泓博医药（301230）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579104507","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579104507?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:57","pubTimestamp":1761865028,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泓博医药发布2025年三季报。截至本报告期末，公司营业总收入5.14亿元，同比上升31.43%，归母净利润3474.96万元，同比上升127.96%。按单季度数据看，第三季度营业总收入1.62亿元，同比上升28.67%，第三季度归母净利润998.82万元，同比上升1462.85%。本报告期泓博医药盈利能力上升，毛利率同比增幅18.06%，净利率同比增幅73.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"gpt_icon":0},{"id":"2579397395","title":"泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579397395","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579397395?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:51","pubTimestamp":1761731491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泓博医药(301230.SZ)发布2025年三季度报告，该公司前三季度营业收入为5.14亿元，同比增长31.43%。归属于上市公司股东的净利润为3474.96万元，同比增长127.96%。归属于上市公司股东的扣除非经常性损益的净利润为2770.95万元，同比增长353.43%。基本每股收益为0.2489元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301230"],"gpt_icon":0},{"id":"2578204950","title":"泓博医药调整股权激励计划授予价格并完成预留授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2578204950","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578204950?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:36","pubTimestamp":1761658599,"startTime":"0","endTime":"0","summary":"中访网数据 上海泓博智源医药股份有限公司于2025年10月27日召开第四届董事会第四次会议，审议通过了调整2024年限制性股票激励计划授予价格及向激励对象授予预留限制性股票的议案。根据公司2024年年度权益分派方案实施情况，本次激励计划的授予价格由12.35元/股调整为12.02元/股。同时，公司向10名激励对象授予了23.00万股预留限制性股票，授予价格为12.02元/股。本次授予的激励对象为公司高级管理人员及核心技术(业务)骨干、外籍员工。公司表示，本次调整及授予事项符合相关法律法规及公司激励计划的规定，已取得必要的批准和授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251028/31745329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2570105260","title":"股市必读：泓博医药（301230）9月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2570105260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570105260?lang=zh_cn&edition=full","pubTime":"2025-09-26 01:00","pubTimestamp":1758819649,"startTime":"0","endTime":"0","summary":"截至2025年9月25日收盘，泓博医药报收于34.72元，下跌0.74%，换手率3.81%，成交量2.93万手，成交额1.03亿元。泓博医药是一家新药研发及商业化生产一站式综合服务商，公司业务涉及的治疗领域众多，其中包括减肥领域。当日关注点来自交易信息汇总：9月25日主力资金净流入469.77万元，显示主力对泓博医药的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600000466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768035526105,"stockEarnings":[{"period":"1week","weight":0.3806},{"period":"1month","weight":0.342},{"period":"3month","weight":0.2366},{"period":"6month","weight":0.1534},{"period":"1year","weight":0.6982},{"period":"ytd","weight":0.3806}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"14019人(较上一季度减少1.34%)","perCapita":"8960股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":" 上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}